BioSpecifics Technologies Corporation
35 Wilbur Street
Lynbrook
New York
11563-2358
United States
Tel: 516-593-7000
Fax: 516-593-7010
Website: http://www.biospecifics.com/
219 articles about BioSpecifics Technologies Corporation
-
BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals
12/2/2020
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the successful completion of its acquisition by Endo International plc (End
-
Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
11/18/2020
Endo International plc announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the previously announced tender offer by Beta Acquisition Corp...
-
BioSpecifics Reports Third Quarter 2020 Financial and Operating Results
11/9/2020
BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, announced its financial results for the third quarter ended September 30, 2020.
-
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of BioSpecifics Technologies Corp. - BSTC
10/21/2020
Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating BioSpecifics Technologies Corp. ("BioSpecifics" or the "Company") ( BSTC ) relating to its proposed acquisition by Endo International PLC. Unde
-
Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™
10/19/2020
- Endo International plc (NASDAQ: ENDP) today announced it has agreed to acquire all of the outstanding shares of BioSpecifics Technologies Corp. (NASDAQ: BSTC), a commercial-stage biopharmaceutical company, for $88.50 in cash per share, or an estimated enterprise
-
BioSpecifics to be Acquired by Endo Pharmaceuticals
10/19/2020
BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that it has entered into a definitive merger agreement under which Endo International plc (NASDAQ: ENDP) will acquire BioSpecifics for an estimated
-
BioSpecifics to Present at the Virtual Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit
9/14/2020
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced that Joseph Truitt , Chief Executive Officer, will present at the virtual O
-
BioSpecifics to Present at the H.C. Wainwright Virtual Healthcare Conference
9/8/2020
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced that Joseph Truitt , Chief Executive Officer, will present at the H
-
BioSpecifics Reports Second Quarter 2020 Financial and Operating Results
8/10/2020
- Highly experienced business development executive, Alex Monteith, named as Senior Vice President and Chief Business Officer - Qwo™ (collagenase clostridium histolyticum-aaes) approved by FDA for treatment of cellulite - Patient dosing initiated in clinical trials for XIAFLEX® in both plantar fibromatosis and adhesive capsulitis
-
BioSpecifics Appoints Alex Monteith as Chief Business Officer
7/20/2020
BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the appointment of Alex Monteith as Senior Vice President and Ch
-
It’s a relatively slow month ahead for July in terms of PDUFA dates for the U.S. FDA. However, there are several dates pending throughout the month. Here’s a look at three for the next two weeks.
-
BioSpace Movers & Shakers, May 15
5/15/2020
Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers. -
BioSpecifics Reports First Quarter 2020 Financial and Operating Results
5/11/2020
- 19% year-over-year increase in royalty revenues for XIAFLEX® - Highly experienced biopharma executive, Joseph Truitt, named as Chief Executive Officer and Mike Sherman and Corey Fishman appointed to Board of Directors - Initiation of CCH studies for plantar fibromatosis and adhesive capsulitis in 2H20 [11-May-2020] WILIMINGTON, Del., May 11, 2020
-
BioSpecifics Names Joseph Truitt as Permanent Chief Executive Officer
5/11/2020
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the appointment of Joseph Truitt as Chief Executive Officer. Mr. Truitt was appoint
-
BioSpecifics Appoints Mike Sherman and Corey Fishman to Board of Directors
4/9/2020
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced that its Board of Directors appointed Mike Sherman and Corey Fishman to serve as Independent Directors, effective immediately.
-
BioSpecifics Appoints Joseph Truitt as Interim Chief Executive Officer
4/9/2020
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer.
-
BioSpecifics Reports Fourth Quarter and Full Year 2019 Financial and Operating Results
3/16/2020
BioSpecifics Technologies Corp. announced its financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.
-
BioSpecifics Reports Third Quarter 2019 Financial and Operating Results
11/8/2019
BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced its financial results for the third quarter ended September 30, 2019 and provided a corporate update.
-
BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer
10/10/2019
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today named life sciences industry veteran Kevin Buchi chief executive officer of BioSpecifics
-
BioSpecifics Technologies Corp. Reports Second Quarter 2019 Financial and Operating Results
8/9/2019
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2019 and provided a corporate update.